390 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Millstone Evans Group LLC

Millstone Evans Group LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 390 shares of the medical research company’s stock, valued at approximately $29,000.

Several other large investors have also made changes to their positions in the business. Quest Partners LLC purchased a new stake in Edwards Lifesciences in the third quarter valued at $406,000. Avior Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the last quarter. Advisors Asset Management Inc. grew its holdings in Edwards Lifesciences by 7.7% during the third quarter. Advisors Asset Management Inc. now owns 11,856 shares of the medical research company’s stock worth $782,000 after acquiring an additional 852 shares during the period. Eagle Asset Management Inc. raised its position in Edwards Lifesciences by 38.0% during the third quarter. Eagle Asset Management Inc. now owns 30,282 shares of the medical research company’s stock valued at $2,006,000 after acquiring an additional 8,346 shares in the last quarter. Finally, Meridian Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter valued at approximately $303,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,303 shares of company stock valued at $3,715,776 over the last quarter. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on EW. Piper Sandler raised their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Barclays increased their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Finally, Evercore ISI reduced their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Stock Performance

NYSE EW opened at $71.43 on Tuesday. The stock’s fifty day moving average is $71.43 and its two-hundred day moving average is $70.42. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $41.99 billion, a P/E ratio of 10.25, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.